- There are no upcoming events available at this time.
. To repair ruptured or pierced organs and tissues, surgeons commonly use staples, sutures and wires to bring and hold the wound edges together so that they can heal. However, these procedures can be difficult to perform in hard-to-reach areas of the body and wounds are often not completely sealed immediately. Recently published in Science Translational Medicine, a study presents a robust solution for the efficient repair of wounds in mechanically challenging body areas. Sidhu Gangadharan, MD, Chief of Thoracic Surgery and Interventional Pulmonology at BIDMC, collaborated with other researchers to demonstrate that a sealant, based on elastin—a human, resilience-imparting protein present in all elastic tissues such as the wall of arteries, skin, and lungs—can be photochemically tuned to effectively seal incisions in arteries and lungs of rats and to repair wounds in the lungs of pigs, all suture and staple-free.
. BIDMC-TVO is pleased to announce Pfizer’s Centers for Therapeutic Innovation (CTI) Fall 2017 call for pre-proposals with submission deadline: Friday, October 13, 2017. The Pfizer CTI program collaborates with leading academic medical centers, the NIH and foundations to speed the translation of novel targets into potential therapeutics. Pfizer offers access to its drug development capabilities and lab facilities for these BIDMC-CTI collaborations. BIDMC Researchers working on large or small molecules for therapeutics in the areas of oncology, inflammation & immunology, cardiovascular & metabolic diseases, neuroscience and rare diseases should apply. Informational office hours will be held on: Tuesday, October 3, 2017, 10am - 5pm at CLS, 18th Floor, Room 1810A, 3 Blackfan Circle, Boston. To schedule a 20 minutes meeting with Nader Halim, PhD (External Science & Innovation, Pfizer) regarding the CTI call for pre-proposals, please e-mail Cindy Wong: firstname.lastname@example.org.
. On Tuesday, October 31 from 12-2 PM, the HMS Initiative for RNA Medicine and the BIDMC Technology Ventures Office will co-host a lunchtime panel discussion in the Pechet Room at the Joseph B. Martin Conference Center. Speakers: Sudhir Agrawal, DPhil; Jeannie T. Lee, MD, PhD; Jason Rhodes, MBA. Moderators: Frank Slack, PhD; Wanni A. Davis, PhD, MBA.
. It takes a cocktail of drugs to treat HIV. It could take a cocktail of antibodies to prevent HIV as well, suggests a study published in Science Translational Medicine. Dan Barouch, MD, PhD, director of the Center for Virology and Vaccine Research at BIDMC, and colleagues found through the study that a cocktail of antibodies is required to protect monkeys against a mixed virus challenge, whereas single antibodies were unable to protect. This data suggests that a mixture of antibodies will likely be more effective than single antibodies for HIV prevention and therapy. “One of the unique features about HIV that is a big challenge for both vaccine and therapeutic development is virus variability,” said Barouch. “There is a huge number of different genetic variants of the virus and there isn't any single antibody that covers all viruses. So, to get complete protection, we will almost certainly need multiple antibodies targeting different regions of the virus and protein.”